Abiraterone, Docetaxel Best With ADT for Metastatic Prostate Cancer

Abiraterone plus prednisolone/prednisone, or docetaxel, combined with ADT may be the most effective therapies for metastatic hormone-naive prostate cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Genitourinary Cancers News Prostate Cancer Source Type: news

Related Links:

The mechanisms by which prostate cancer shifts from an indolent castration-sensitive phenotype to lethal castration-resistant prostate cancer (CRPC) are poorly understood. Identification of clinically relevant genetic alterations leading to CRPC may reveal potential vulnerabilities for cancer therapy. Here we find that CUB domain-containing protein 1 (CDCP1), a transmembrane protein that acts as a substrate for SRC family kinases (SFKs), is overexpressed in a subset of CRPC. Notably, CDCP1 cooperates with the loss of the tumor suppressor gene PTEN to promote the emergence of metastatic prostate cancer. Mechanistically, we ...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Conclusions: There were increased risks of cardiovascular disease with the use of GnRH agonists and degarelix, but not with bicalutamide monotherapy. This is the first study to observe increased cardiovascular risks with degarelix, but the cause of this association is unclear and merits further investigation.
Source: Epidemiology - Category: Epidemiology Tags: Cardiovascular Disease Source Type: research
Conclusion: Ascertaining prostate cancer progression through self-report provides an efficient and valid approach to enhancing existing cancer cohorts with updated data on progression status. See video abstract at, http://links.lww.com/EDE/B658.
Source: Epidemiology - Category: Epidemiology Tags: Cancer Source Type: research
Publication date: Available online 5 April 2020Source: European UrologyAuthor(s): Giorgio Gandaglia, Alberto Martini, Guillaume Ploussard, Nicola Fossati, Armando Stabile, Pieter De Visschere, Hendrik Borgmann, Isabel Heidegger, Fabian Steinkohl, Alexander Kretschmer, Giancarlo Marra, Romain Mathieu, Cristian Surcel, Derya Tilki, Igor Tsaur, Massimo Valerio, Roderick Van Den Bergh, Piet Ost, Paolo Gontero, Francesco Montorsi
Source: European Urology - Category: Urology & Nephrology Source Type: research
The Bone Morphogenetic Protein (BMP) pathway is a member of the TGFβ signaling family and has complex roles in cancer. BMP signaling is rarely mutated and can be frequently overexpressed in many human cancers. The dichotomous role of BMPs as both tumor promoters and suppressors appears to be largely context based in both the cancer cell and the surrounding microenvironment. Myeloid cells including macrophages and neutrophils have been shown to be tumor promoting when stimulated from BMPs. We found that conditional deletion of BMPR1a in myeloid cells (LysMCre) restricts tumor progression in a syngeneic mouse prostate c...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, we initially reveal the association of LINC01600 with radioresponse in PCa and identify its potential target PCGs for further basic and clinical research.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThe specific association between PTEN deletion or ERG rearrangement and the recurrence of prostate cancer (PC) treated with radical prostatectomy (RP) or brachytherapy is still unelaborated. Therefore, we performed a comprehensive meta ‑analysis to understand the impact of these factors on cancer recurrence.MethodsA comprehensive literature search was performed in November 2018 based on PUBMED, EMBASE and Web of science database. Hazard ratio (HR) for biochemical recurrence free (BRF) which was defined as a PSA greater than or equal to 0.4  ng/mL after RP or another therapy for any detectable PSA a...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
An international team of researchers created a framework of recommendations to help patients and healthcare professionals make decisions regarding radiation treatment for patients with prostate cancer during the COVID-19 pandemic.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Journal of Proteome ResearchDOI: 10.1021/acs.jproteome.0c00006
Source: Journal of Proteome Research - Category: Biochemistry Authors: Source Type: research
Publication date: Available online 4 April 2020Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Kaili Wang, Weijie Zhang, Zihan Wang, Ming Gao, Xinying Wang, Wenchao Han, Nan Zhang, Xia Xu
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Docetaxel | Hormones | Prednisolone | Prednisone | Prostate Cancer | Taxotere